Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGK1 | P00558 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | SLC1A5 | Q15758 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.31 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1193487 | 0.84 | PGK1 (0.42) | PGK1GAAL3MBTL1NPC1SLC1A5 | |
| SCHEMBL29770333 | 0.84 | PGK1 (0.42) | PGK1GAAL3MBTL1NPC1SLC1A5 | |
| SCHEMBL2650312 | 0.82 | L3MBTL1 (0.42) | POLBL3MBTL1 | |
| SCHEMBL16268733 | 0.80 | PGK1 (0.38) | PGK1GAANPC1SLC1A5NOTUM | |
| SCHEMBL2683377 | 0.78 | NPC1 (0.41) | PGK1GAAPOLBL3MBTL1NPC1 | |
| SCHEMBL19914318 | 0.78 | ALDH1A1 (0.40) | PGK1GAANPC1SLC1A5NOTUM | |
| SCHEMBL30038728 | 0.76 | POLB (0.50) | POLBL3MBTL1NPC1 | |
| SCHEMBL19411031 | 0.76 | POLB (0.50) | POLBL3MBTL1NPC1 | |
| SCHEMBL8074938 | 0.76 | GAA (0.42) | PGK1GAAL3MBTL1NPC1SLC1A5 | |
| SCHEMBL21729544 | 0.76 | PDE2A (0.37) | POLBL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101238131-A | Bridged piperazine and piperidine derivatives as CCR1 antagonists | NOVARTIS AG (CH) | 2008-08-06 | — | — | CN | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| US-20070196270-A1 | Compounds As Ccri Antagonists | HENG RICHARD | 2007-08-23 | — | — | US | disclosed |
| EP-1794164-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCR1 ANTAGONISTS | Novartis AG (CH) | 2007-06-13 | — | — | EP | disclosed |
| WO-2005103054-A2 | BRIDGED PIPERAZINE AND PIPERIDINE DERIVATIVES AS CCRI ANTAGONISTS | NOVARTIS AG (CH) | 2005-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070196270-A1 | Compounds As Ccri Antagonists | CCR1, CCR10, CCR4 | PGK1 3377/4885GAA 2746/4885POLB 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.